

Supplementary Table 1.
Cancer drugs targeting the identified virus-host protein-protein interactions of SARS-CoV-2

Pathway	Target Gene	Drug	Status	Cancer Treatment Investigation	Effect on <i>in vitro</i> Viral Infection
Cell cycle / DNA damage	NEK9	Dabrafenib	Approved	BRAF-mutation related tumors	N/A
	RIPK1	Ponatinib	Approved	leukemia, lung	Neutral
	RIPK1	Pazopanib	Approved	solid tumors	Neutral
Metabolism	IMPDH2	Mycophenolic acid	Approved	leukemia	Neutral
	NDUFAF2	Metformin	Approved	oral, breast, prostate, colorectal, liver	Inhibitory
Epigenetics / Chromatin	HDAC2	Valproic acid	Approved	glioblastoma	Neutral
	DNMT1	Azacitidine	Approved	leukemia	N/A
	BRD2/4	ABBV-744	Clinical trials	leukemia	Neutral
	BRD2/4	CPI-0610	Clinical trials	solid tumors, leukemia	Neutral
Translation / RNA processing	mTOR	Rapamycin	Approved	solid tumors	Neutral
	mTOR	Sapanisertib	Clinical trials	solid tumors	Neutral
	eIF4A	Zotatifin	Clinical trials	solid tumors	Inhibitory
	MNK1/2	Tomivosertib	Clinical trials	breast, prostate, lymphoma	Neutral
	CRM1	Selinexor	Approved	myeloma, solid tumors	N/A
MARK-kinases	MARK2	Midostaurin	Approved	leukemia	Activating
	MARK2/3	Ruxolitinib	Approved	pancreatic, blood	Activating
Membrane transport	ABCC1	Daunorubicin	Approved	leukemia	Activating
	ABCC1	Verapamil	Approved	lung, colorectal, gastric, kidney	Neutral
Stress response	HSP90	Onalespib	Clinical trials	solid tumors	Inhibitory
Cul2 complex	NAE	Pevonedistat	Clinical trials	solid tumors, leukemia	N/A
Stress granule regulation	CSNKA2	Silmitasertib	Approved	medulloblastoma	Neutral
Autophagy	SIGMAR1	Hydroxychloroquine	Approved	solid tumors	Inhibitory
Replication	-	Brivudine	Clinical trials	colorectal	Activating